The impartiality of the domain has been questioned, because Eli Lilly and Company, Merck & Co., and Pfizer are the main contributors to the NABP application. Previously, that application was challenged by Public Citizen, Knowledge Ecology International, and the Canadian International Pharmacy Association.[7]